Gene therapy · Gene replacement · developed by Krystal Biotech
KB801 is an ophthalmic suspension of a replication-defective, non-integrating herpes simplex virus type 1-based vector that delivers a functional, full-length human nerve growth factor gene. It is being studied in neurotrophic keratitis, a disease of the cornea.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06999733 | Phase 1/2 | Neurotrophic Keratitis | Recruiting | KRYS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Neurotrophic Keratitis
Updated Oct 18, 2026. Something wrong or missing? Report it on the KRYS page.
See KRYS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KRYS catalysts and pipeline →